Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning

Stopped Inability to recruit the number of patients established in the study protocol (34 of 40)

Conditions

• Graft Versus Host Disease

Interventions

• DRUG: Alemtuzumab

Sponsor

CABYC

Collaborators

• [object Object]